SPOKANE, WA – 09-06-2025 – Precision Quantomics Inc., a leader in proteomics and quantitative systems pharmacology is proud to announce the receipt of a new National Institutes of Health (NIH) award supporting the development of recombinant human enzyme kits to advance personalized medicine and drug metabolism research.
This latest award builds upon Precision Quantomics’ previous NIH STTR grant, which centered on strategies to improve drug disposition in populations historically underrepresented in clinical trials. The new grant tackles a critical dimension of pharmacogenomics and personalized medicine — the genetic variability in drug metabolism across US patient groups.
Drug metabolism is significantly impacted by genetic polymorphisms, which can alter drug efficacy and safety. Medications such as clopidogrel, warfarin, tamoxifen, and irinotecan exhibit genotype-dependent differences in metabolism and clinical response, creating risks of adverse drug reactions or reduced therapeutic benefit. Current in vitro testing often fails to capture this genetic diversity, relying on tools and reagents from limited donor pools.
To address these shortcomings, Precision Quantomics will design and generate recombinant human enzyme panels that represent clinically important genetic variants in drug-metabolizing enzymes, including cytochromes P450, N-acetyltransferases, and thiopurine S-methyltransferase. The project will use advanced mammalian expression systems, validated quantitative proteomics, standardized protein engineering, quality controls, and pre-aliquoted reagents to create ready-to-use commercial kits for integration into standard drug metabolism assays.
“This project represents a crucial next step in ensuring that drug development strategies reflect the genetic diversity of the US population,” said Dr. Bhagwat Prasad, Chief Scientific Officer at Precision Quantomics. “By providing recombinant enzyme kits, we are equipping researchers and pharmaceutical companies with practical tools to assess drug metabolism and efficacy in genetically polymorphic populations.”
“The NIH’s continued support strengthens our vision of a future where precision systems drive patient-centric drug development — bringing us closer to therapies truly tailored to each individual,” added Chandima Bandaranayaka, CEO of Precision Quantomics. “Building on our earlier STTR grant, this initiative provides translational tools that enable developers to address genetic variability, personalize dosing, and reduce outcome gaps across patient populations.”
Christy Watson, Vice President of Research & Development at Precision Quantomics, emphasized the translational potential: “These enzyme kits will allow companies to better predict metabolism and pharmacokinetics for diverse patient groups, supporting more personalized approaches and safer therapies.”
